Journal of Drugs in Dermatology最新文献

Evaluating Topical Nitric Oxide Formulations Against an Atopic Dermatitis Methicillin-Resistant S. Aureus Isolate in a Porcine Infection Model. 评估局部一氧化氮制剂对猪感染模型中耐甲氧西林金黄色葡萄球菌分离物的特应性皮炎。

IF 1.8 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-10-01 DOI: 10.36849/JDD.8830

Stephen C Davis, Joel Gil, Michael Solis, Ryan Strong, Roger Cassagnol

{"title":"Evaluating Topical Nitric Oxide Formulations Against an Atopic Dermatitis Methicillin-Resistant S. Aureus Isolate in a Porcine Infection Model.","authors":"Stephen C Davis, Joel Gil, Michael Solis, Ryan Strong, Roger Cassagnol","doi":"10.36849/JDD.8830","DOIUrl":"https://doi.org/10.36849/JDD.8830","url":null,"abstract":"Background: Atopic dermatitis (AD) is a skin disorder characterized by reduced skin barrier function, which often leads to recurring infections, predominantly by Staphylococcus aureus and methicillin-resistant S. aureus, that exacerbate disease severity. Managing these infections is made challenging by antibiotic resistance and biofilm formation. Nitric oxide (NO) has emerged as a promising antimicrobial treatment that can disperse biofilm and may provide an alternative treatment for AD infections.Methods: This study evaluated the antimicrobial efficacy of 3 topical NO-releasing formulations at various concentrations against established MRSA infections, from an AD-derived isolate, in a porcine wound infection model. Partial thickness wounds were inoculated and, after 48 hours of biofilm formation, were treated daily with NO formulations or vehicle control, or left untreated. Wounds were recovered for baseline, day 4, or day 7 bacterial enumeration.Results: All tested NO-releasing formulations substantially reduced MRSA burden compared with baseline counts, and most effectively with the highest concentrations. 20% NO+GEL resulted in a significant reduction of 99.23% compared with baseline at day 7. The 16% NO+UNG treatment, compared with the untreated control, had bacterial reductions on day 4 and day 7 of greater than 99.5%. The greatest reduction of 99.97% (>3 Log CFU/mL) was observed for 6% NO+CREAM compared with the untreated control group at day 7.Conclusions: NO-releasing treatments have considerable efficacy against MRSA infections and biofilm. These findings support the potential of NO as an antimicrobial treatment for AD patients, and further evaluation should be conducted to assess clinical efficacy.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 10","pages":"1003-1011"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients With Atopic Dermatitis: A Retrospective Chart Review. 黑人和非裔美国成人特应性皮炎患者dupilumab相关不良事件的发生率：回顾性图表回顾。

IF 1.8 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-10-01 DOI: 10.36849/JDD.08749

Ikenna Anusionwu, Kevin Puerta Durango, Tatiana M Barrera, Temitayo Ogunleye, Susan C Taylor, Nicholas Mollanazar

引用次数: 0

Understanding Topical Steroid Withdrawal: Where Are We Now? 理解局部类固醇戒断：我们现在在哪里？

IF 1.8 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-10-01 DOI: 10.36849/JDD.1025

Nikkia Zarabian, Mina Farah, Adam Friedman

引用次数: 0

An Exosome Regenerative Complex Plus Microneedling Promotes Hair Growth in Subjects With Self-Perceived Thinning Hair. 外泌体再生复合体加微针促进自我感觉头发稀疏受试者的头发生长。

IF 1.8 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-10-01 DOI: 10.36849/JDD.9244

Glynis Ablon

{"title":"An Exosome Regenerative Complex Plus Microneedling Promotes Hair Growth in Subjects With Self-Perceived Thinning Hair.","authors":"Glynis Ablon","doi":"10.36849/JDD.9244","DOIUrl":"https://doi.org/10.36849/JDD.9244","url":null,"abstract":"Thinning hair affects the quality of life of affected men and women but has limited treatment options. A novel technology refines exosomes from stem cells to create a concentrated complex that is quickly absorbed into the scalp to deliver growth factors, peptides, coenzymes, minerals, amino acids, and vitamins (Exosome Regenerative Complex+®. BENEV, Inc.; Mission Viejo, CA). This study assessed the efficacy and safety of the Exosome Regenerative Complex applied following microneedling on the scalp of subjects with self-perceived thinning hair. Enrolled subjects were male (n=15) and female (n=15) with a mean (SD) age of 50.2 (10.9) years (range, 26-65 years). Subjects were treated on days 0, 30, 60, and 90, with a final assessment on day 120. Trichoscopy assessments showed this treatment significantly increased terminal and vellus hair counts (P<0.0001) and decreased hair shedding on day 120 (P<0.01), increased mean follicular units per cm² (P<0.0001), and decreased inter-follicular distance (P<0.0001). On day 120, the investigator rating for improved hair quality was 97% and improved hair growth was 83%. Subject satisfaction with treatment results was high with no reported adverse events. The combined use of an Exosome Regenerative Complex combined with RF microneedling appears to be an effective and well-tolerated treatment for hair loss in men and women. ClinicalTrials.gov NCT06571799.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 10","pages":"988-994"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

INDIVIDUAL ARTICLE: VEHICLES MATTER. 个别文章：车辆很重要。

IF 1.8 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-10-01 DOI: 10.36849/JDD.025411

Leon Kircik

引用次数: 0

1% Colloidal Oatmeal Cream/Baby Wash Regimen Improved Atopic Dermatitis in Pediatric Patients From First Use. 1%胶体燕麦霜/婴儿沐浴方案从首次使用开始改善儿科患者的特应性皮炎。

IF 1.8 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-10-01 DOI: 10.36849/JDD.9095

Gabrielle Kosmoski, Diana Friscia, M Catherine Mack, Laura M Brooks, Carrie W Cobb, Zoe D Draelos

{"title":"1% Colloidal Oatmeal Cream/Baby Wash Regimen Improved Atopic Dermatitis in Pediatric Patients From First Use.","authors":"Gabrielle Kosmoski, Diana Friscia, M Catherine Mack, Laura M Brooks, Carrie W Cobb, Zoe D Draelos","doi":"10.36849/JDD.9095","DOIUrl":"https://doi.org/10.36849/JDD.9095","url":null,"abstract":"Background and objective: Atopic dermatitis (AD) affects 15% to 20% of children. Evidence supporting the effectiveness of colloidal oatmeal-based moisturizers in improving mild-to-moderate AD is accumulating. Data on use with a bathing routine, where compromised skin could be affected, is lacking. This study evaluated the effectiveness and tolerability of 1% colloidal oatmeal-containing cream and gentle baby wash in children with AD.Methods: In this open-label, single-arm study of children 3 to 72 months old with mild-to-moderate AD, 1% colloidal oatmeal-containing cream was applied twice daily, and a gentle baby wash was used ≥3 times/week for 4 weeks.Primary endpoint: mean change from baseline at day 28 in the Eczema Area Severity Index (EASI) and Atopic Dermatitis Severity Index (ADSI) total scores. Adverse events (AEs), tolerability, skin barrier (SB), Infant Dermatitis Quality of Life (IDQoL), sleep (Brief Infant Sleep Questionnaire-Revised; BISQ-R), and pruritus were evaluated. Assessments were performed at baseline and on days 1, 3, 7, and 28.Results: Twenty-nine of 31 enrollees completed the study. At all visits, improvements from baseline in EASI, ADSI, IDQoL, and pruritus were significant (P<0.05). SB significantly improved at most visits. Two AEs were reported and led to study discontinuation (papular rash; contact dermatitis).Conclusions: The study regimen was effective and well-tolerated in this pediatric population with AD. Improvements occurred as early as day 1, with a rapid reduction in pruritus and increased well-being.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 10","pages":"979-987"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Refractory Pruritus Secondary to Linear IgA Bullous Dermatosis Treated Successfully With Nemolizumab: A Case Report. 奈莫单抗成功治疗线性IgA大疱性皮肤病继发难治性瘙痒1例

IF 1.8 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-10-01 DOI: 10.36849/JDD.9162

Sarah Romanelli, Jeremy Orloff, Marley Cutrona, Kristina Navrazhina, Alice Gottlieb

引用次数: 0

The Emerging Role of Oncodermatology in a Hemato-Oncology Unit in a Tertiary Hospital. 肿瘤皮肤科在三级医院血液肿瘤科的新兴作用。

IF 1.8 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-10-01 DOI: 10.36849/JDD.8965

Rhiannon Nancarrow-Lei, Emily Durity, Yasmin Alfallouji, Claire Martyn-Simmons, Evangelia Panagou

{"title":"The Emerging Role of Oncodermatology in a Hemato-Oncology Unit in a Tertiary Hospital.","authors":"Rhiannon Nancarrow-Lei, Emily Durity, Yasmin Alfallouji, Claire Martyn-Simmons, Evangelia Panagou","doi":"10.36849/JDD.8965","DOIUrl":"https://doi.org/10.36849/JDD.8965","url":null,"abstract":"Background: Our dermatology department consistently receives the largest proportion of internal on-call referrals from the Hematology-Oncology Department. Individuals with hematological malignancies are particularly susceptible to dermatologic conditions secondary to immunosuppression and multi-agent exposure, which can impact cancer therapy, leading to morbidity and mortality.Methods: Our primary objective was to analyze the range of dermatologic conditions observed in patients with hematologic malignancies and to identify potential associations with anticancer therapies. We conducted a retrospective, single-center review of acute hematology-oncology referrals to our on-call service between August 2020 and November 2022. Consultations were identified retrospectively through the on-call referral log.Results: One hundred and thirty-four (134) patients were included. The most common diagnoses were cutaneous adverse drug eruptions (22%), leukemia or lymphoma cutis (13%), infections (13%), and acneiform eruptions (10%). Notably, cutaneous drug reactions were more prevalent in patients with myeloid neoplasms (32%). Acneiform eruptions predominantly occurred in patients with myeloid lineage malignancies.Conclusion: Dermatology plays a vital role in providing consultative services to patients with hematology-oncology conditions. With the emergence of novel therapies, the landscape of dermatologic complications in this population is evolving. Consequently, the demand for dermatology expertise is expected to increase to facilitate prompt diagnosis and management and to ensure optimal patient outcomes.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 10","pages":"1018-1023"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months. 美国儿童、青少年和成人特应性皮炎患者的杜匹单抗持续时间超过24个月

IF 1.8 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-10-01 DOI: 10.36849/JDD.8931

J Morel Symons, Janis L Breeze, Stevan G Severtson, Stefan Weiss, Dharm S Patel

{"title":"Real-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months.","authors":"J Morel Symons, Janis L Breeze, Stevan G Severtson, Stefan Weiss, Dharm S Patel","doi":"10.36849/JDD.8931","DOIUrl":"https://doi.org/10.36849/JDD.8931","url":null,"abstract":"Background: Dupilumab has demonstrated benefits in patients with atopic dermatitis (AD), but there is limited information on real-world rates of dupilumab persistence and supplementation with topical and systemic treatments beyond adult populations.Objective: This retrospective cohort study evaluated real-world dupilumab use among children (<13 years), adolescents (13–17 years), and adults (≥18 years) with moderate-to-severe AD, who initiated dupilumab (March 2017 to September 2021) in the United States.Methods: The OM1 PremiOM™ AD dataset was used to assess dupilumab treatment persistence and treatment supplementation over a 24-month period.Results: Of 5200 eligible patients who initiated dupilumab, 208 were children, 430 were adolescents, and 4562 were adults. Dupilumab persistence decreased consistently over 24 months of follow-up. The probability of dupilumab persistence at 12 and 24 months was 79.8% and 70.8% in children, 81.9% and 63.1% in adolescents, and 73.2% and 55.7% in adults, respectively. Across all patients, treatment supplementation increased over time; 31.5% received supplemental systemic therapy, and 62.1% received topical medications at 24 months.Conclusions: Over a 2-year period, dupilumab persistence generally decreased while treatment supplementation increased for all patient groups, indicating a considerable proportion of patients with AD have unaddressed treatment needs.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 10","pages":"996-1002"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

INDIVIDUAL ARTICLE: The Utility of Delgocitinib in Chronic Hand Eczema. 个别文章：德尔古替尼在慢性手部湿疹中的应用。

IF 1.8 4区医学

Journal of Drugs in Dermatology Pub Date : 2025-10-01 DOI: 10.36849/JDD.025412

Naiem T Issa, JiaDe Yu, Christopher G Bunick, Leon Kircik

引用次数: 0